Masonic Cancer Center, University Of Minnesota
Clinical trials sponsored by Masonic Cancer Center, University Of Minnesota, explained in plain language.
-
Kitchen spice and olive oil tested as potential tumor treatment
Disease control OngoingThis early-stage study is testing whether daily doses of curcumin (from turmeric) and a special high-phenolic olive oil are safe and might help reduce skin tumors in adults with Neurofibromatosis Type 1 (NF1). The 23 participants take these supplements twice daily for up to a yea…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test new drug to supercharge Cancer-Fighting CAR-T cells
Disease control TerminatedThis early-stage trial is testing whether adding an experimental drug called E7777 before standard CAR-T cell therapy can improve results for adults with aggressive B-cell lymphomas that have returned or not responded to prior treatments. The drug aims to help the CAR-T cells wor…
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Boosted stem cells aim to speed recovery in aggressive blood cancers
Disease control OngoingThis study is testing whether specially grown cord blood stem cells can help patients with high-risk blood cancers recover their immune systems faster after a transplant. Participants receive a transplant using these expanded stem cells after strong chemotherapy. Researchers are …
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope: rebuilding broken immune systems with donor cells
Disease control OngoingThis study is testing a treatment to rebuild the immune system in people with severe inherited immune deficiencies. Patients receive stem cells from a donor, which are meant to grow into healthy new immune cells. The goal is to control the disease and reduce life-threatening infe…
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo aims to shield brain from powerful cancer Treatment's harsh side effects
Disease control OngoingThis early-stage study is testing whether giving two existing drugs—dexamethasone (into the spine) and simvastatin (a pill)—can safely prevent or reduce serious brain-related side effects in adults with lymphoma receiving a powerful treatment called CAR-T cell therapy. The main g…
Phase: EARLY_PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists track rare disease drug in tiniest patients
Disease control OngoingThis study aims to understand how a drug called laronidase works in very young children with a rare genetic disorder (MPS I) who are getting a stem cell transplant. Researchers will observe and measure the drug levels in the blood before and after the transplant. The children wil…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New hope for kids with devastating genetic diseases
Disease control OngoingThis study is testing a stem cell transplant procedure for children and adults with severe, inherited metabolic disorders and a rare bone disease. The goal is to see if using a specific drug combination can help the donor cells successfully take hold in the patient's body while k…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Engineered immune cells battle advanced blood cancers in new trial
Disease control OngoingThis study is testing several FDA-approved CAR-T cell therapies for patients whose blood cancers have returned or not responded to standard treatments. It involves about 150 participants with conditions like acute lymphoblastic leukemia and various lymphomas. The main goals are t…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Feb 27, 2026 15:20 UTC
-
Ancient herb tested to soothe cancer Survivors' stress
Symptom relief TerminatedThis small, early-stage study is testing whether taking kava, a plant-based supplement, can safely help reduce anxiety and stress in people who have finished cancer treatment. Participants take either kava or a placebo pill for two weeks, then switch after a break. The study is c…
Phase: EARLY_PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Symptom relief
Last updated Mar 25, 2026 14:08 UTC
-
Scientists measure What's really in your vape
Knowledge-focused OngoingThis study aims to gather initial safety data on a specific, standardized e-cigarette. Researchers are measuring the levels of various chemicals in the bodies of 47 adult smokers who switch completely to using this e-cigarette. The goal is to create reference data to help underst…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:58 UTC
-
Cancer's hidden cost: the exhausting hours spent on treatment tasks
Knowledge-focused OngoingThis study aims to measure how much time people with metastatic breast or advanced ovarian cancer spend on treatment-related activities like appointments, travel, medication management, and paperwork. Participants carry a smartphone for 28 days to track their activities and compl…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
Scientists trace hidden path to cancer in smokeless tobacco
Knowledge-focused OngoingThis study aims to understand how a specific chemical (nornicotine) found in smokeless tobacco products might turn into a known cancer-causing agent (NNN) inside the user's body. Researchers are enrolling 55 adult smokeless tobacco users to measure these chemicals in their urine.…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC